Please login to the form below

Not currently logged in


This page shows the latest LMTX news and features for those working in and with pharma, biotech and healthcare.

AbbVie takes anti-tau drug into phase II for Alzheimer's

AbbVie takes anti-tau drug into phase II for Alzheimer's

Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in

Latest news

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    LMTX is thought to reduce the accumulation of the tau protein, which normally stabilizes neurons, into potentially toxic tangles. ... The LMTX data were presented at the Alzheimer's Association International Conference in Toronto.

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....